Hi Ol'cs,
what do you think about this?
http://neurotalk.psychcentral.com/sh...light=prosavin
Watching the video the results seems very encouraging, and only a single injection is sufficient. Excellent recent reports on its safety and tolerability, with good improvements in motor functions. For me, at this moment, it seems to me the best way to try.
http://news.sky.com/story/9567/revol...for-parkinsons
http://www.foxnews.com/health/2012/0...inson-disease/
http://www.oxfordbiomedica.co.uk/page.asp?pageid=29
http://www.oxfordbiomedica.co.uk/use...m%20Report.pdf
ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function
ProSavin® has demonstrated a long-term safety profile, now over five years post-treatment for the first
patient treated with a 1x dose, and the Company now has a total of approximately 38 patient years of
safety data for the ProSavin® clinical programme. All 15 patients treated demonstrated an
improvement in motor function at the six-month efficacy endpoint relative to baseline. In addition, all
six patients who received the highest (5x) dose have now completed follow-up assessments 12
months post-treatment where ProSavin® continues to mediate improvements in motor function.
Non-clinical programme for product optimisation on track
Oxford BioMedica is currently evaluating a more potent formulation to ensure the greatest chance of
success in future randomised studies and to increase the commercial opportunity by offering
extended patent protection and a relative reduction in cost of goods. The Company initiated a nonclinical
programme in H1 2012 to evaluate the efficacious dose range of the enhanced product
construct using the gold standard MPTP model of Parkinson’s disease. The non-clinical programme
will evaluate improvements in motor function, in addition to Positron Emission Tomography (PET)
data to assess dopaminergic activity. Progress is on track and Oxford BioMedica expects early data
to start to emerge from Q4 2012 onwards which the Company will share with potential partners. The
full non-clinical programme is expected to complete in Q3 2013.